Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

About this update from Voyager Therapeutics, Inc.

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational tau silencing gene therapy for Alzheimer’s disease (AD), in a late-breaking presentation at the American Society of Gene & Cell Therapy’s (ASGCT) 2026 Annual Meeting in Boston, May 11-15, 2026. Data presented showed that VY1706 was well tolerated, with no adverse clinical pathology or histopathological findings up to the highest dose tested (5E13 vg/kg), and reduced tau protein up to 64% in key brain regions of non-human primates (NHPs) at 13 weeks following a single IV dose. Voyager’s U.S. Food and Drug Administration (FDA) investigational new drug (IND) application process for VY1706 is on track for Q2 2026 to support projected first-in-human dosing in AD patients in H2 2026. “These latest 3-month GLP toxicology data with tau silencing gene therapy VY1706 are consistent with the robust preclinical data package we have established to date, and we look forward to advancing into clinical trials for Alzheimer’s disease later this year,” said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics. “VY1706 has the potential to be the first gene therapy approach to targeting tau, and we believe the ability to knock down intracellular and extracellular tau with a one-time, IV dose could be transformative for patients living with Alzheimer’s disease.” Late-Breaking Oral PresentationIntravenous delivery of VY1706, a CNS penetrant AAV gene therapy for Alzheimer’s disease, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs (#163). Data from Voyager’s seven additional oral and poster presentations at ASGCT demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability. Oral Presentation Directed evolution of muscular and neuromuscular capsid variants in both mice and non-human primates (#422). Alzheimer’s Disease TargetsIntravenous delivery of a bi-functional AAV gene therapy t...

View stock analysis, news, and events for Voyager Therapeutics, Inc.